RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells

FASEB Journal

Volumn 28, Issue 9, 2014, Pages 4158-4168

  Lee, Seunghyung ^a   Goldfinger, Lawrence E ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Angiogenesis; Growth factors; Transcription factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MATRIGEL; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAL INTERACTING PROTEIN OF 76; RECOMBINANT VASCULOTROPIN; SECRETOME; UNCLASSIFIED DRUG; VASCULOTROPIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RALBP1 PROTEIN, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CARCINOMA; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR REGRESSION; ANIMAL; AORTA; APOPTOSIS; CELL HYPOXIA; CYTOLOGY; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; LEWIS CARCINOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; AORTA; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL HYPOXIA; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GTPASE-ACTIVATING PROTEINS; HYPOXIA-INDUCIBLE FACTOR 1; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907192278     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-255711     Document Type: Article

References (61)

1. Folkman, J. (1992) The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3, 65-71
2. Weis, S. M., and Cheresh, D. A. (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17, 1359-1370
3. Hicklin, D. J., and Ellis, L. M. (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011-1027
4. Jullien-Flores, V., Dorseuil, O., Romero, F., Letourneur, F., Saragosti, S., Berger, R., Tavitian, A., Gacon, G., and Camonis, J. H. (1995) Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J. Biol. Chem. 270, 22473-22477
5. Park, S. H., and Weinberg, R. A. (1995) A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. Oncogene 11, 2349-2355
6. Awasthi, S., Cheng, J., Singhal, S. S., Saini, M. K., Pandya, U., Pikula, S., Bandorowicz-Pikula, J., Singh, S. V., Zimniak, P., and Awasthi, Y. C. (2000) Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry 39, 9327-9334
7. Awasthi, S., Cheng, J. Z., Singhal, S. S., Pandya, U., Sharma, R., Singh, S. V., Zimniak. P., and Awasthi, Y. (2001) Functional reassembly of ATP-dependent xenobiotic transport by the N-and C-terminal domains of RLIP76 and identification of ATP binding sequences. Biochemistry 40, 4159-4168
8. Awasthi, S., Sharma, R., Yang, Y., Singhal, S. S., Pikula, S., Bandorowicz-Pikula, J., Singh, S. V., Zimniak, P., and Awasthi, Y. C. (2002) Transport functions and physiological significance of 76 kDa Ral-binding GTPase activating protein (RLIP76). Acta Biochim. Pol. 49, 855-867
9. Goldfinger, L. E., Ptak, C., Jeffery, E. D., Shabanowitz, J., Hunt, D. F., and Ginsberg, M. H. (2006) RLIP76 (RalBP1) is an R-Ras effector that mediates adhesion-dependent Rac activation and cell migration. J. Cell Biol. 174, 877-888
10. Sharma, R., Gupta, S., Singh, S. V., Medh, R. D., Ahmad, H., LaBelle, E. F., and Awasthi, Y. C. (1990) Purification and characterization of dinitrophenylglutathione ATPase of human erythrocytes and its expression in other tissues. Biochem. Biophys. Res. Commun. 171, 155-161
11. Awasthi, S., Singhal, S. S., Srivastava, S. K., Zimniak, P., Bajpai, K. K., Saxena, M., Sharma, R., Ziller, S. A., 3rd, Frenkel, E. P., and Singh, S. V. (1994) Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J. Clin. Invest. 93, 958-965
12. Awasthi, Y. C., Singhal, S. S., Gupta, S., Ahmad, H., Zimniak, P., Radominska, A., Lester, R., and Sharma, R. (1991) Purification and characterization of an ATPase from human liver which catalyzes ATP hydrolysis in the presence of the conjugates of bilirubin bile acids and glutathione. Biochem. Biophys. Res. Commun. 175, 1090-1096
13. Singhal, S. S., Singhal, J., Yadav, S., Dwivedi, S., Boor, P. J., Awasthi, Y. C., and Awasthi, S. (2007) Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res. 67, 4382-4389
14. Singhal, S. S., Roth, C., Leake, K., Singhal, J., Yadav, S., and Awasthi, S. (2009) Regression of prostate cancer xenografts by RLIP76 depletion. Biochem. Pharmacol. 77, 1074-1083
15. Singhal, S. S., Awasthi, Y. C., and Awasthi, S. (2006) Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. 66, 2354-2360
16. Awasthi, S., Singhal, S. S., Awasthi, Y. C., Martin, B., Woo, J. H., Cunningham, C. C., and Frankel, A. E. (2008) RLIP76 and cancer Clin. Cancer Res. 14, 4372-4377
17. Goldfinger, L. E., and Lee, S. (2013) Emerging treatments in lung cancer - targeting the RLIP76 molecular transporter. Lung Cancer Targets Ther. 4, 61-69
18. Lee, S., Wurtzel, J. G., Singhal, S. S., Awasthi, S., and Goldfinger, L. E. (2012) RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization. Cancer Res. 72, 5165-5173
19. McMahon, G. (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl. 1), 3-10
20. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22
21. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev. 25, 581-611
22. Aonuma, M., Saeki, Y., Akimoto, T., Nakayama, Y., Hattori, C., Yoshitake, Y., Nishikawa, K., Shibuya, M., and Tanaka, N. G. (1999) Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression. Int. J. Exper. Pathol. 80, 271-281
23. Terman, B., and Stoletov, K. (2001) VEGF and tumor angiogenesis. Einstein Quar. J. Biol. Med. 18, 59-66
24. Choi, K. S., Bae, M. K., Jeong, J. W., Moon, H. E., and Kim, K. W. (2003) Hypoxia-induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol. 36, 120-127
25. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613
26. Yan, J., Liu, Q., Dou, Y., Hsieh, Y., Liu, Y., Tao, R., Zhu, D., and Lou, Y. (2013) Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against beta-amyloid peptide-induced human endothelial cells apoptosis. J. Ethnopharmacol. 147, 456-466
27. Nagy, M. A. (2011) HIF-1 is the commander of gateways to cancer. Cancer Sci. Ther. 3, 35-40
28. Dery, M. A., Michaud, M. D., and Richard, D. E. (2005) Hypoxia-inducible factor 1: regulation by hypoxic and nonhypoxic activators. Int. J. Biochem. Cell. Biol. 37, 535-540
29. Semenza, G. L. (2009) HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20, 51-56
30. Yi, T., Papadopoulos, E., Hagner, P. R., and Wagner, G. (2013) Hypoxia-inducible factor-1alpha (HIF-1alpha) promotes capdependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions. J. Biol. Chem. 288, 18732-18742
31. Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., and Semenza, G. L. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277, 38205-38211
32. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., and Whitelaw, M. L. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861
33. Ziello, J. E., Jovin, I. S., and Huang, Y. (2007) Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 80, 51-60
34. Semenza, G. L. (2009) HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr. Pharm. Des. 15, 3839-3843
35. Semenza, G. L. (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207-214
36. Muz, B., Khan, M. N., Kiriakidis, S., and Paleolog, E. M. (2009) Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthrit. Res. Ther. 11, 201
37. Malo, M. S., Mozumder, M., Chen, A., Mostafa, G., Zhang, X. B., and Hodin, R. A. (2006) pFRL7: an ideal vector for eukaryotic promoter analysis. Anal. Biochem. 350, 307-309
38. Goel, H. L., and Mercurio, A. M. (2013) VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871-882
39. Wurtzel, J. G., Kumar, P., and Goldfinger, L. E. (2012) Palmitoylation regulates vesicular trafficking of R-Ras to membrane ruffles and effects on ruffling and cell spreading. Small GTPases 3, 139-153
40. Karar, J., and Maity, A. (2011) PI3K/AKT/mTOR Pathway in angiogenesis. Front. Mol. Neurosci. 4, 51
41. Moriya R, Takahashi K, Kitahara A, Onuma H, Handa K, Sumitani Y, Tanaka, T., Katsuta, H., Nishida, S., Itagaki, E., Inukai, K., and Ishida, H. (2014) Possible involvement of PI3K-dependent pathways in the increased VEGF release from osteoblastic cells preloaded with palmitate in vitro. Biochem. Biophys. Res. Commun. 445, 275-281
42. Zhao, W., Guo, W., Zhou, Q., Ma, S. N., Wang, R., Qiu, Y., Jin, M., Duan, H. Q., and Kong, D. (2013) In vitro antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells. Int. J. Mol. Sci. 14, 13577-13591
43. Takahashi, K., Miyokawa-Gorin, K., Handa, K., Kitahara, A., Moriya, R., Onuma, H., Sumitani, Y., Tanaka, T., Katsuta, H., Nishida, S., Yoshimoto, K., Ohno, H., and Ishida, H. (2013) Endogenous oxidative stress, but not ER stress, induces hypoxia- independent VEGF120 release through PI3K-dependent pathways in 3T3-L1 adipocytes. Obesity 21, 1625-1634
44. Volm, M., Koomagi, R., Mattern, J., and Stammler, G. (1997) Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 17, 99-103
45. Marneros, A. G. (2009) Tumor angiogenesis in melanoma. Hematol. Oncol. Clin. North Am. 23, 431-446, vii-viii.
46. Mahabeleshwar, G. H., and Byzova, T. V. (2007) Angiogenesis in melanoma. Semin. Oncol. 34, 555-565
47. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., and Seed, B. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725
48. Gerber, H. P., Kowalski, J., Sherman, D., Eberhard, D. A., and Ferrara, N. (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60, 6253-6258
49. Kishimoto, J., Ehama, R., Ge, Y., Kobayashi, T., Nishiyama, T., Detmar, M., and Burgeson, R. E. (2000) In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am. J. Pathol. 157, 103-110
50. Leake, K., Singhal, J., Nagaprashantha, L. D., Awasthi, S., and Singhal, S. S. (2012) RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer PLoS One 7, e34582
51. Limaverde-Sousa, G., Sternberg, C., and Ferreira, C. G. (2014) Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat. Rev. 40, 548-557
52. Sehrawat, A., Yadav, S., Awasthi, Y. C., Basu, A., Warden, C., and Awasthi, S. (2013) P300 regulates the human RLIP76 promoter activity and gene expression. Biochem. Pharmacol. 85, 1203-1211
53. Singhal, S. S., Yadav, S., Singhal, J., Zajac, E., Awasthi, Y. C., and Awasthi, S. (2005) Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem. Pharmacol. 70, 481-488
54. Margutti, P., Matarrese, P., Conti, F., Colasanti, T., Delunardo, F., Capozzi, A., Garofalo, T., Profumo, E., Riganò, R., Siracusano, A., Alessandri, C., Salvati, B., Valesini, G., Malorni, W., Sorice, M., and Ortona, E. (2008) Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 111, 4559-4570
55. Gille, J. (2006) Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp. Dermatol. 15, 175-186
56. Motl, S. (2005) Bevacizumab in combination chemotherapy for colorectal and other cancers. Am. J. Health Syst. Pharm. 62, 1021-1032
57. Sparano, J. A., Gray, R., Giantonio, B., O'Dwyer, P., and Comis, R. L. (2004) Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin. Cancer Res. 10, 1206-1211
58. Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., and Jain, R. K. (2000) Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha - > hypoxia response element - > VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60, 6248-6252
59. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24
60. Kozin, S. V., Boucher, Y., Hicklin, D. J., Bohlen, P., Jain, R. K., and Suit, H. D. (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39-44
61. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., and Boucher, Y. (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565-5570